Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.

The clinical efficacy of combined therapy (CAB) has been clearly recognized by the results of the STRIVE trial. Although enzalutamide has shown a stronger effect on CRPC, bicultamide, a classical anti-androgen, has shown a significant effect. In addition, it can be deduced that CAB is a strong tool for hormone naïve advanced prostate cancer. Cost-effective evaluation for CAB with bicultamide or enzalutamide is warranted, especially for the resource-limited cohort.